IRIS
TRIVELLIN, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.718
NA - Nord America 1.646
EU - Europa 436
SA - Sud America 319
Continente sconosciuto - Info sul continente non disponibili 97
AF - Africa 44
OC - Oceania 11
Totale 4.271
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.563
SG - Singapore 986
CN - Cina 394
BR - Brasile 266
VN - Vietnam 148
IT - Italia 80
FI - Finlandia 59
IE - Irlanda 59
CA - Canada 52
GB - Regno Unito 45
DE - Germania 37
HK - Hong Kong 36
FR - Francia 28
IN - India 28
RU - Federazione Russa 27
AR - Argentina 24
JP - Giappone 23
MX - Messico 18
BD - Bangladesh 15
CZ - Repubblica Ceca 13
ES - Italia 13
PK - Pakistan 13
BE - Belgio 12
ID - Indonesia 12
AU - Australia 11
SE - Svezia 11
IQ - Iraq 10
ZA - Sudafrica 10
AT - Austria 9
NL - Olanda 9
PL - Polonia 9
VE - Venezuela 9
EC - Ecuador 7
UZ - Uzbekistan 7
DZ - Algeria 6
MA - Marocco 6
TR - Turchia 6
AZ - Azerbaigian 5
CH - Svizzera 5
CL - Cile 5
PH - Filippine 5
TN - Tunisia 5
UA - Ucraina 5
DO - Repubblica Dominicana 4
EG - Egitto 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CI - Costa d'Avorio 3
CO - Colombia 3
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
MY - Malesia 3
UY - Uruguay 3
ET - Etiopia 2
HN - Honduras 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
MD - Moldavia 2
NG - Nigeria 2
NO - Norvegia 2
PE - Perù 2
PS - Palestinian Territory 2
QA - Qatar 2
BB - Barbados 1
DK - Danimarca 1
GT - Guatemala 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
MR - Mauritania 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 4.174
Salva come PNG Salva come JPEG
Città #
Singapore 444
San Jose 229
Ashburn 205
Shanghai 193
The Dalles 163
Dallas 91
New York 91
Council Bluffs 88
Beijing 83
Boardman 82
Los Angeles 60
Dublin 59
Helsinki 58
Ho Chi Minh City 50
Santa Clara 44
Hong Kong 31
Milan 31
Hanoi 29
São Paulo 27
Buffalo 21
Seattle 19
Phoenix 18
Gatineau 16
Moscow 15
Houston 14
Brno 12
Brooklyn 11
Liège 11
Rio de Janeiro 11
Boston 10
Melbourne 10
Montreal 10
Chicago 9
Johannesburg 9
Stockholm 9
Tokyo 9
Chandler 8
Charlotte 8
Lahore 8
Manchester 8
Orem 8
Rome 8
Toronto 8
Atlanta 7
Da Nang 7
London 6
Milwaukee 6
Munich 6
Naples 6
Tashkent 6
Vienna 6
Baghdad 5
Baku 5
Curitiba 5
Eustis 5
Guarulhos 5
Haiphong 5
Porto Alegre 5
Southwark 5
Warsaw 5
Washington 5
Assago 4
Belo Horizonte 4
Buenos Aires 4
Can Tho 4
Chennai 4
Denver 4
Fortaleza 4
Frankfurt am Main 4
Higashiosaka 4
Hải Dương 4
Mexico City 4
Miami 4
Nashville 4
New Delhi 4
Quito 4
San Francisco 4
St Petersburg 4
São José dos Campos 4
Abidjan 3
Amsterdam 3
Bishkek 3
Bến Tre 3
Campinas 3
Caxias do Sul 3
Figino 3
Guayaquil 3
Hangzhou 3
Juiz de Fora 3
Kuala Lumpur 3
La Marque 3
Leiden 3
Manaus 3
Monterrey 3
Nairobi 3
Newark 3
Ninh Bình 3
Orlando 3
Paris 3
Philadelphia 3
Totale 2.563
Salva come PNG Salva come JPEG
Nome #
Use of G protein-coupled receptor 101 inhibitor, antagonist or inverse agonist for prevention and/or therapeutic treatment of diseases selected from group consisting of acromegaly and gigantism 174
Characterization of GPR101: Transcripts Structure, Expression Pattern, and Signal Transduction Pathways 144
Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management 93
Alteration of the immunophenotype and cytokine profiles in patients affected by neuroendocrine neoplasms 91
Characterization of GPR101 Expression Across Different Species 87
Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia 80
X-linked acro-gigantism (X-LAG): a new form of infant-onset pituitary gigantism 76
X-Linked Acro-Gigantism (X-LAG) Due to Microduplications of Chromosome Xq26: A New Disorder and Implications for Acromegaly 75
A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred 68
An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations 67
Characterization of GPR101 transcript structure and expression patterns 67
Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression 65
miR-107 inhibits the expression of aryl hydrocarbon receptor interacting protein (AIP) and is potentially involved in pituitary tumorigenesis 65
Comparing models and experimental structures of the GPR101 receptor: Artificial intelligence yields highly accurate models 64
CD40LG duplications in patients with X-LAG syndrome commonly undergo random X-chromosome inactivation 63
The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors 63
Germline mutations in a G protein identify signaling cross-talk in T cells 61
Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess 61
FAF1 Gene Involvement in Pituitary Corticotroph Tumors 61
Xq26.3 Duplication in a Boy With Motor Delay and Low Muscle Tone Refines the X-Linked Acrogigantism Genetic Locus 60
GPR101: Modeling a constitutively active receptor linked to X-linked acrogigantism 60
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers 60
Chaperones, somatotroph tumors and the cyclic AMP (cAMP)-dependent protein kinase (PKA) pathway 60
AIP and its interacting partners 60
Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus 57
Characterization of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations in Familial Isolated Pituitary Adenoma Families 55
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors 54
Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland 54
Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up 53
Characterization of the adiponectin promoter + Cre recombinase insertion in the Tg(Adipoq-cre)1Evdr mouse by targeted locus amplification and droplet digital PCR 53
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion 52
PAM variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas 52
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 51
Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease 50
Genetics of gigantism and acromegaly 50
Interaction of AIP with protein kinase A (cAMP-dependent protein kinase) 49
Increased expression of miR-34a explains the low AIP protein level present in 50% of sporadic somatotropinomas 49
AIP Mutation in Pituitary Adenomas REPLY 49
Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants 49
A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype 49
Evaluation of CDKN1B germline mutations in a cohort of acromegalic patients with evidences of multiple neoplasia 49
Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome 48
Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism 48
Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly? 47
MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro 46
Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal alpha-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition 46
The direct impact of pegvisomant on osteoblast functions and bone development 44
The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells 44
Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease 44
Evaluation of p27KIP1 germline mutations in familial phaeochromocytoma and clinically suspected MEN1 patients 43
Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations 42
Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway 42
MicroRNAs: Suggested role in pituitary adenoma pathogenesis 42
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 42
SATB1: a gene involved in pituitary development may have a role in somatotroph tumors 42
Evaluation of mutations in aryl hydrocarbon receptor interacting protein (AIP) in acromegalic sporadic cases and in one FIPA family 42
Oncogene-induced senescence in pituitary adenomas and carcinomas 40
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study 40
Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers 39
Large genomic aberrations in corticotropinomas are associated with greater aggressiveness 39
Hereditary endocrine tumours: Current state-of-the-art and research opportunities: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis 38
The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish 38
Diagnosis and Treatment of Parasellar Lesions 38
GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency 37
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients 37
Stable GPR101 over-expressing cell lines as an invaluable tool for functional studies, ligand screening, and the identification of deregulated genes/pathways in patients with X-linked acrogigantism 37
Familial pituitary apoplexy as the only presentation of a novel AIP mutation 36
Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation 36
Gigantism, Acromegaly, and GPR101 Mutations REPLY 36
Screening for GPR101 defects in pediatric pituitary corticotropinomas 35
Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo, Brazil 35
Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice 35
Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation 34
MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics 33
Familial isolated pituitary adenomas: An emerging clinical entity 33
Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas 32
GHRH excess and blockade in X-LAG syndrome 32
Is IGSF1 involved in human pituitary tumor formation? 32
Pituitary gigantism: update on molecular biology and management 31
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 29
Hereditary endocrine tumours: Current state-of-the-art and research opportunities: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA) 29
IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction 28
Totale 4.271
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.708
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.708
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202210 0 0 0 0 0 0 0 0 1 4 4 1
2022/202396 4 2 2 2 3 2 0 1 6 4 0 70
2023/2024706 50 31 145 21 36 80 90 50 13 24 61 105
2024/2025952 37 4 18 15 11 139 113 54 94 220 129 118
2025/20262.318 321 143 120 234 131 129 622 116 113 143 114 132
2026/2027189 69 120 0 0 0 0 0 0 0 0 0 0
Totale 4.271